A Peek At What Teva Pharmaceutical Industries Limited (TEVA) Insiders Are Doing

Teva Pharmaceutical Industries Limited (NYSE:TEVA) saw an upside of 0.40% to close Friday at $10.16 after adding $0.04 on the day. The 5-day average trading volume is 6,941,160 shares of the company’s common stock. It has gained $10.23 in the past week. An average of 8,469,355 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 7,193,650.

TEVA’s 1-month performance is 9.84% or $0.78 on its low of $8.59 reached on 09/21/21. The company’s shares have touched a 52-week low of $8.24 and high of $13.30, with the stock’s rally to the 52-week high happening on 02/09/21. YTD, TEVA has achieved 5.28% or $0.51. However, the current price is down -23.61%% from the 52-week high price.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Insider Transactions

On Aug 10, 62 days have gone by since the last insider trading activity for Teva Pharmaceutical Industries Limited (TEVA). Fridriksdottir Hafrun (Executive VP, Global R&D) most recently sold 50,860 shares at $9.95 per share on Aug 10. This transaction cost the insider $506,021. Executive VP Global Operations, Drape Eric, sold 40,000 shares at a price of $11.01 on May 21. Then, on May 11, Exec. VP Chief Legal Officer Stark David Matthew sold 37,884 shares at a price of $10.22 per share. This transaction amounted to $387,125.

Valuation Metrics

Teva Pharmaceutical Industries Limited (TEVA) has a trailing price-to-earnings (P/E) ratio of 23.00 for the broader industry and 31.93 for the sector. The company’s PE ratio for the last five years has touched a high of 3295.00 and a low of 20.37. TEVA stock has a beta of 1.37. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 0.68 while the price-to-book (PB) in the most recent quarter is 1.09.

Teva Pharmaceutical Industries Limited’s quick ratio for the period ended June 29 was 0.70, with the current ratio over the same period at 1.00 meaning that TEVA stock is not able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 2.09, while the total debt to equity was 2.43. In terms of profitability, the gross margin trailing 12 months is 47.60%. The trailing 12-month EBITDA margin is 27.70% while for the period ending June 29; Teva Pharmaceutical Industries Limited’s operating margin was -17.90%. The firm’s gross profit as reported stood at $7.73 billion against revenue of $16.66 billion.

Earnings Surprise

For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 1.02% to $3.91 billion, while revenue of $3.98 billion was -1.84% off the previous quarter. Analysts expected TEVA to announce $0.59 per share in earnings in its latest quarter, but it posted $0.59, representing a 0.00% surprise. EBITDA for the quarter stood at more than $887.0 million. TEVA stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 37.88 billion, with total debt at $25.58 billion. Shareholders hold equity totaling $1.1 billion

Technical Picture

Let’s look briefly at Teva Pharmaceutical Industries Limited (TEVA) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 08 October was 72.95% to suggest the stock is trending Overbought, with historical volatility in this time period at 30.18%.

The stock’s 5-day moving average is $9.90, reflecting a +4.74% or $0.46 change from its current price. TEVA is currently trading +10.55% above its 20-day SMA, -4.78% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +4.85% and +5.83% respectively.

Stochastic %K and %D was 93.13% and 87.54% and the average true range (ATR) pointed at 0.30. The RSI (14) points at 66.81%, while the 14-day stochastic is at 95.73% with the period’s ATR at 0.30. The stock’s 9-day MACD Oscillator is pointing at 0.21 and 0.54 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for Teva Pharmaceutical Industries Limited (NYSE: TEVA), UBS downgraded it to a Neutral rating. They previously had a Buy rating on the stock. Analysts offering their rating for TEVA stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate TEVA as a “sell,”, while 13 advise that investors “Hold.” 1 analysts have rated the stock as underweight. 2 rates the stock as overweight while 1 have offered a “buy” rating.

What is TEVA’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $10.00 and a high of $14.00, with their median price target at $11.00. Looking at these predictions, the average price target given by analysts is for Teva Pharmaceutical Industries Limited (TEVA) stock is $11.54.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

spot_img

Hot Topics

Related Videos

Related Videos

Related Articles

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

592

100% free. stop anytime no spam